JCO

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Health, Clinical Trials, Health Technology, Oncology, Breast cancer, Neoplasm, Patient, Cancer, NTRA, HER2, Woman, MRD, RFS, Recurrence, MD, Doctor of Philosophy, OS, JCO, Genetic testing, Imperial College London, DNA, Plasma, Central Statistics Office (India), Medical imaging

The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS).

Key Points: 
  • The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS).
  • Patients were followed for up to 12 years after surgery and adjuvant chemotherapy, with blood samples collected semi-annually and then analyzed using Signatera.
  • In a multivariate analysis, ctDNA status was the most significant factor associated with RFS and OS.
  • “The findings also bolster the evidence for long-term monitoring of high-risk breast cancer patients, who often face late recurrences.”

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Retrieved on: 
Monday, April 22, 2024
Oncology, Data Management, Health, Technology, Health Technology, Software, Biotechnology, Radiation, Patient, Prostate, Risk, Safety, JCO, MVA, Prostate cancer, Disease, Urology, Intelligence, Neoplasm, Biomarker, Waiting, GRID, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress.
  • The findings make the Decipher test the only gene expression test to have treatment-outcome data from a prospective, multi-center, phase 2, randomized trial in the AS population.
  • “The findings from the ENACT trial analysis demonstrate that the Decipher Prostate test is a predictor of disease progression on AS,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
  • The findings also demonstrated the use of Decipher GRID (Genomic Resource for Intelligent Discovery) as a research tool to help advance scientific understanding of prostate cancer.

New Clinical Study Identifies Personalized Treatment Options for Metastatic Non-Small Cell Lung Cancer With Plasma Proteome Testing

Retrieved on: 
Thursday, April 25, 2024
Cancer, FCS, JCO, NSCLC, Prophet, Society, Patient, Research, Plasma, Physician, Nursing

"We cannot stress enough the importance of research in the oncology field," says FCS President & Managing Physician Lucio N. Gordan, MD .

Key Points: 
  • "We cannot stress enough the importance of research in the oncology field," says FCS President & Managing Physician Lucio N. Gordan, MD .
  • "Furthermore, our own physicians are making remarkable strides in advancing oncology care for patients.
  • By incorporating precision oncology tactics, we are uncovering new applications of existing therapies to drive the best results, as was done in this study."
  • "This study is pivotal in developing a precise approach to treating cancer based on the unique cellular properties of the patient, not the cancer type.

Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230

Retrieved on: 
Wednesday, March 27, 2024
OS, Harvard Medical School, DOI, Radium-223, Prostate cancer, Gene expression, Metastasis, Doctor of Pharmacy, JCO, Assistant, Patient, Tap, Biomarker, RNA, Chinese, Quality of life, CRPC, Senior, Hospital, Prognosis, CTC, Radiation therapy, PSA, FDA, CTCM, Medical imaging

ANDOVER, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223. The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230).

Key Points: 
  • The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230 ).
  • “Radium-223 is a valuable treatment option for patients with mCRPC, but better biomarkers are needed to identify patients most likely to benefit from therapy.
  • Additionally, imaging assessment in patients with bone-predominant disease has also been limited in patients receiving radium-223.
  • Upon controlling for known prognostic markers, PSA and tAP, the presence of baseline CTC AR-V7 expression was most predictive of OS among patients receiving radium-223.

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Retrieved on: 
Monday, March 18, 2024
Survival, JCO, Caregiver, Therapy, Palliative care, Patient, Ethics, Journal, Mouse, Research, Hebrew University of Jerusalem, Anxiety, MD, Nature, Quality of life, Adjustment disorder, World Health Organization, Adjustment, ASCO, Molecular Psychiatry, WHO, Paper, FDA, PBM

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:PBM) ("Psyence Biomed" or the "Company") today issued a statement welcoming the results of a recent study finding evidence that nature-derived psilocybin may be demonstrably more therapeutic than synthetic psilocybin.

Key Points: 
  • The study presents evidence that nature (mushroom)-derived psilocybin delivers a “more potent and prolonged effect” on “neuroplasticity” than its synthetic analog.
  • “Neuroplasticity” is increasingly recognized as the gold standard by which the therapeutic efficacy of psychedelic pharmaceutical medicines can be measured.
  • The Psyence Biomed study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the Palliative Care context.
  • Neither Psyence Biomedical nor any of its investors or affiliates funded or in any way sponsored the Hebrew University study.

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, February 29, 2024
ONC201, MD, ASCO, Growth, Neuro-Oncology (journal), Manuscript, HGG, Conference, Human, Society, Patient, Journal, Survival, JCO, Pharmaceutical industry

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2023 and provided an operational update.
  • Chimerix reported a net loss of $18.2 million, or $0.20 per basic and diluted share, for the fourth quarter of 2023, compared to a net loss of $21.0 million, or $0.24 per basic and diluted share for the fourth quarter of 2022.
  • General and administrative expenses decreased to $5.2 million for the fourth quarter of 2023, compared to $5.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss fourth quarter and full-year 2023 financial results and provide a business update today at 8:30 a.m.

Cancer Care Specialists of Illinois Partners with Canopy to Optimize Continuous Care Management

Retrieved on: 
Thursday, February 29, 2024
Program management, ASCO, EHR, Nursing, Patient, PCM, NCCA, JCO, Partnership

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Cancer Care Specialists of Illinois (CCSI), a 22-site community oncology practice and member of the National Cancer Care Alliance (NCCA) , today announced a partnership with Canopy , the first Intelligent Care Platform for oncology.

Key Points: 
  • NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Cancer Care Specialists of Illinois (CCSI), a 22-site community oncology practice and member of the National Cancer Care Alliance (NCCA) , today announced a partnership with Canopy , the first Intelligent Care Platform for oncology.
  • Through this collaboration, CCSI aims to optimize its Principal Care Management (PCM) program and streamline continuous care management to further enhance patient outcomes.
  • "Cancer Care Specialists of Illinois is committed to providing every patient with personalized, comprehensive care using state-of-the-art equipment and treatment methods," said Rhonda Luther, Chief Operating Officer of Cancer Care Specialists of Illinois.
  • CCSI is also partnering with Canopy to scale its Principal Care Management (CCM/PCM) program to support continuous care efforts and other quality care initiatives.

‘AlignMiracle’ Makes Waves in the World of Direct Clear Aligner, Featured in the Prestigious International Clinical Journal, JCO

Retrieved on: 
Monday, December 4, 2023
Research, Apps, Applications, Technology, Medical Devices, Publishing, Dental, Communications, Software, Health, Science, JCO, Orthodontics, ODS, Journal of Clinical Orthodontics, Dentist, History, Patient, Multimedia, Journal, Doctor of Philosophy, FDA, KFDA, CMO, Certification, Publication, Dentistry

ODS Co., Ltd. , a leading provider of Direct Clear Aligner (also known as “Direct Print Aligner”), today announced the publication of treatment cases using direct clear aligners in the October 2023 issue of the Journal of Clinical Orthodontics (JCO), one of the most respected publications in the field of orthodontics.

Key Points: 
  • ODS Co., Ltd. , a leading provider of Direct Clear Aligner (also known as “Direct Print Aligner”), today announced the publication of treatment cases using direct clear aligners in the October 2023 issue of the Journal of Clinical Orthodontics (JCO), one of the most respected publications in the field of orthodontics.
  • Founded in 1967, JCO is an esteemed international academic journal with a rich history of over five decades.
  • It serves as a platform for disseminating the latest techniques and innovative approaches in orthodontics.
  • With its comprehensive coverage and global reach, JCO has garnered a loyal readership among orthodontic clinicians worldwide.

Veracyte Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Radiation therapy, IVD, GAAP, Acquisition, Prostate cancer, JCO, Society, Prostate, Growth, Webcast, Abstract, American Society for Radiation Oncology, Cancer, ASTRO, Table, Patient, GM, GRID, Pharmaceutical industry, Video game, Medical imaging, Illumina

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023.
  • Total revenue for the third quarter of 2023 was $90.1 million, an increase of 19% compared to $75.6 million reported in the third quarter of 2022.
  • Total gross margin for the third quarter of 2023, including the amortization of acquired intangible assets, was 64%, compared to 59% in the third quarter of 2022.
  • Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update.

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Retrieved on: 
Monday, November 6, 2023
Science, Breast, Report, ESMO, Progression-free survival, Therapy, Metastatic breast cancer, RL, Congress, European Society for Medical Oncology, Cyclin-dependent kinase 4, Conference, Breast cancer, Research, Cancer, Estrogen receptor alpha, Poster, JCO, Sheba Medical Center, ESR1, Fuchs, Prognosis, RM, Oncology, Estrogen, Clinical Cancer Research, Mortality, Patient, Fulvestrant, Mutation, Pharmaceutical industry, Medical imaging, Liquor, Woman, Incidence

The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.

Key Points: 
  • The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.
  • The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022.
  • Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology (ESMO) Congress 2022.
  • 5Jeselsohn R, De Angelis C, Brown M, et al: The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.